Flag of the European Union EU Clinical Trials Register Help

Clinical trials for New York Heart Association Functional Classification

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: New York Heart Association Functional Classification. Displaying page 1 of 1.
    EudraCT Number: 2019-000885-39 Sponsor Protocol Number: 02289 Start Date*: 2021-01-12
    Sponsor Name:Universitätsmedizin Göttingen
    Full Title: Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure
    Medical condition: Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002960-27 Sponsor Protocol Number: P-6708H Start Date*: 2007-07-23
    Sponsor Name:Pharma Nord ApS
    Full Title: Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on Symptoms, Biomarker status (BNP) and long-term Outcome (hospitalisation/mort...
    Medical condition: Chronic heart failure for more than 6 weeks, in NYHA class III or IV. Age>18 years; males and females. Optimal medical treatment of heart failure according to the investigators opinion.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-001747-31 Sponsor Protocol Number: CLCZ696D2301 Start Date*: 2013-09-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure pat...
    Medical condition: Heart failure with preserved ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10069211 Diastolic heart failure LLT
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) AT (Completed) BG (Completed) DE (Prematurely Ended) ES (Completed) NO (Completed) GB (Completed) NL (Completed) CZ (Completed) IT (Completed) SE (Completed) BE (Completed) DK (Completed) GR (Completed) FI (Completed) HR (Completed) PL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2018-004828-11 Sponsor Protocol Number: RECHMPL18_0038_prom_7574 Start Date*: 2022-01-10
    Sponsor Name:University Hospital of Montpellier
    Full Title: Phosphodiesterase-type 5 inhibitors in adult and adolescent patients with univentricular heart disease: a multi-center, randomized, double blind phase III study
    Medical condition: adult and adolescent patients with univentricular heart diseases and pulmonary arterial pressure
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004133-16 Sponsor Protocol Number: IH141 Start Date*: 2015-02-19
    Sponsor Name:Hull and east Yorkshire Hospitals Trust
    Full Title: Exploratory multicentre prospective double blinded randomised controlled pilot study of the effect of intravenous iron supplementation(Monofer)in iron deficient but not anaemic patients with Chroni...
    Medical condition: Chronic Kidney Disease stages 3b to 5 with iron deficiency
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000868-42 Sponsor Protocol Number: B3461045 Start Date*: 2016-09-26
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN SUBJECTS DIAGNOSED WITH TRANSTHYR...
    Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) CZ (Completed) DE (Completed) SE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000516-42 Sponsor Protocol Number: CLX003-IMP-2-170121 Start Date*: 2018-03-20
    Sponsor Name:Cell Therapy Ltd (trading as Celixir)
    Full Title: A Phase IIB, Randomised, Double-Blinded, Placebo-Controlled Study of the Efficacy and Safety of Intramyocardial Injection of Allogeneic Human Immunomodulatory Progenitor (iMP) cells in Patients Und...
    Medical condition: Ischaemic heart disease post MI
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10048858 Ischaemic cardiomyopathy PT
    20.0 10007541 - Cardiac disorders 10023024 Ischaemic heart disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001503-26 Sponsor Protocol Number: FER-CARS-03 Start Date*: 2008-10-17
    Sponsor Name:Vifor Pharma - Vifor (International) AG
    Full Title: EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac function in patients with iron deficiencY and chronic Heart Failure (EFFICACY-HF)
    Medical condition: Ambulatory patients with stable symptomatic chronic CHF (congestive heart failure) and iron deficiency.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008908 Chronic heart failure LLT
    9.1 10002062 Anaemia iron deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) DE (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023788-16 Sponsor Protocol Number: P-Monofer-CABG-01 Start Date*: 2011-03-22
    Sponsor Name:Pharmacosmos A/S
    Full Title: A Randomized, Prospective, Double-Blind, Comparative Placebo-Controlled Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-anemic Patients Undergoing Elective o...
    Medical condition: Non-anemic Patients Undergoing Elective or Sub-Acute CABG, Valve Replacement or a Combination thereof
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004863 10054312 Anemia postoperative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-000103-34 Sponsor Protocol Number: CL2-16257-062 Start Date*: 2005-07-13
    Sponsor Name:Institut de Recherches Internationales Servier [...]
    1. Institut de Recherches Internationales Servier
    2. Laboratorios Servier S.L. (For Spain only)
    Full Title: Evaluation of the effects of 3 successive oral dosages (2.5; 5; 7.5 mg b.i.d.) of ivabradine in patients with stable moderate to severe systolic chronic heart failure treated with beta-blockers. A ...
    Medical condition: Chronic systolic heart failure
    Disease: Version SOC Term Classification Code Term Level
    3.3 10007558 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004034-41 Sponsor Protocol Number: 21267983 Start Date*: 2005-11-25
    Sponsor Name:Genzyme Europe B.V.
    Full Title: Evaluation of Skeletal Myoblast Transplant for Treating Ischemic Heart Failure Phase 2 Study Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Study
    Medical condition: Ischemic Heart Failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006953-77 Sponsor Protocol Number: 27-12-2021 Start Date*: 2022-04-11
    Sponsor Name:Aarhus University Hospital
    Full Title: Treatment effects of Bisoprolol and Verapamil in symptomatic patients with non-obstructive hypertrophic cardiomyopathy
    Medical condition: Non-obstructive Hypertrophic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007636 Cardiomyopathy PT
    20.0 10007541 - Cardiac disorders 10049813 Non-obstructive cardiomyopathy PT
    27.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    20.0 10007541 - Cardiac disorders 10061029 Cardiomyopathy primary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003536-92 Sponsor Protocol Number: CY6031 Start Date*: 2022-05-09
    Sponsor Name:Cytokinetics, Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of CK-3773274 in Adults with Symptomatic Hypertrophic Cardiomyopathy and Left Ventric...
    Medical condition: obstructive hypertrophic cardiomyopathy (oHCM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DK (Completed) ES (Ongoing) NL (Completed) CZ (Completed) PL (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002530-23 Sponsor Protocol Number: MYK-461-005 Start Date*: 2018-10-04
    Sponsor Name:MyoKardia, Inc.
    Full Title: A Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
    Medical condition: Hypertrophic Cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) PT (Completed) ES (Completed) CZ (Completed) BE (Completed) NL (Completed) PL (Completed) DK (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003603-37 Sponsor Protocol Number: V87_25 Start Date*: 2014-02-04
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 when Administered to Adult and Elderl...
    Medical condition: Pandemic Influenza
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004862 10070436 H5N1 influenza LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004278-23 Sponsor Protocol Number: CT-P42_3.1 Start Date*: 2021-03-16
    Sponsor Name:CELLTRION Inc.
    Full Title: A Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in Comparison with Eylea in Patients with Diabetic Macular Edema
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) HU (Completed) CZ (Completed) PL (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2021-000125-27 Sponsor Protocol Number: EORTC-1976-STBSG-QLG-ETF Start Date*: 2022-05-31
    Sponsor Name:EORTC AISBL/IVZW
    Full Title: TOLERANCE: a 3 arm randomized study on healTh-related quality Of Life of EldeRly pAtients with advaNced soft tissue sarComa undergoing doxorubicin every three weeks or doxorubicin weekly or cycloph...
    Medical condition: Advanced/metastatic soft tissue sarcoma
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Prematurely Ended) NL (Completed) CY (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005723-37 Sponsor Protocol Number: 2020/3187 Start Date*: 2021-03-24
    Sponsor Name:Gustave Roussy
    Full Title: Phase 2, Open label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in patients with advanced and/or unresectable Non-Small Cell Lung Cancer (NSCLC), with biomarker analysis to cha...
    Medical condition: Adult patients with metastatic and/or unresectable Non-Small Cell Lung Cancer (NSCLC) who progressed on at least one line and not more than three lines of prior therapy for metastatic/unresectable ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005473-22 Sponsor Protocol Number: 20101-23101 Start Date*: 2013-09-26
    Sponsor Name:EORTC
    Full Title: Very early FDG-PET/CT-response adapted therapy for advanced stage Hodgkin Lymphoma, a randomized phase III non-inferiority study of the EORTC Lymphoma Group.
    Medical condition: Advanced stage Hodgkin's lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 23 15:34:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA